The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
In FY 2020-2021 (upto 12th January 2021) Jan Aushadhi Kendras have completed sales of Rs. 484 crores at 7,064 Pradhan Mantri Bhartiya Jan Aushadhi Kendras
This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers both in the government and private sectors including ICDS workers will receive the vaccine during this phase.
Subscribe To Our Newsletter & Stay Updated
